Pages that link to "Q52973062"
Jump to navigation
Jump to search
The following pages link to Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. (Q52973062):
Displaying 50 items.
- Cancer immunotherapy: moving beyond current vaccines (Q24548229) (← links)
- Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 (Q24617636) (← links)
- Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma (Q28067023) (← links)
- Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma (Q30412300) (← links)
- Immunity to melanoma antigens: from self-tolerance to immunotherapy (Q30440584) (← links)
- Clinical applications of a peptide-based vaccine for glioblastoma. (Q33668575) (← links)
- EGFRvIII-targeted vaccination therapy of malignant glioma (Q33758459) (← links)
- Design and evaluation of antigen-specific vaccination strategies against cancer. (Q34046858) (← links)
- Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine (Q34059854) (← links)
- Immunotherapy of melanoma (Q34383950) (← links)
- Biological and clinical developments in melanoma vaccines (Q34452007) (← links)
- Tracking T cells with tetramers: new tales from new tools (Q34632077) (← links)
- Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines (Q34657707) (← links)
- Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? (Q34669820) (← links)
- Identification of tumour-associated T-cell epitopes for vaccine development (Q34718188) (← links)
- Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. (Q34898366) (← links)
- Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining (Q35212680) (← links)
- Clinical application of dendritic cells in cancer vaccination therapy (Q35219339) (← links)
- Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. (Q35595698) (← links)
- Peptide-based vaccines for cancer immunotherapy (Q35681508) (← links)
- T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? (Q35728607) (← links)
- Vaccination with T cell-defined antigens (Q35779384) (← links)
- Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. (Q35809463) (← links)
- Overview of melanoma vaccines and promising approaches (Q35855054) (← links)
- Understanding the response to immunotherapy in humans (Q36017877) (← links)
- Dendritic cells as therapeutic vaccines against cancer (Q36085614) (← links)
- Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity (Q36099441) (← links)
- Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses. (Q36234992) (← links)
- Supernatural T cells: genetic modification of T cells for cancer therapy (Q36328805) (← links)
- Trial watch: Peptide vaccines in cancer therapy (Q36476100) (← links)
- Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma (Q36834545) (← links)
- Vaccine therapy for melanoma: current status and future directions (Q36889580) (← links)
- Functional heterogeneity of vaccine-induced CD8(+) T cells (Q36908627) (← links)
- Cancer vaccines for established cancer: how to make them better? (Q37118174) (← links)
- Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in p (Q37379219) (← links)
- Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? (Q37744997) (← links)
- Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy? (Q37952804) (← links)
- Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. (Q37981764) (← links)
- Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review (Q38059513) (← links)
- Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. (Q38291127) (← links)
- The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection (Q40113293) (← links)
- Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma (Q40568899) (← links)
- Monitoring immune responses in cancer patients receiving tumor vaccines (Q40588550) (← links)
- Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model (Q42455463) (← links)
- Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial (Q44235754) (← links)
- Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides (Q48614800) (← links)
- Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells. (Q52367953) (← links)
- Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. (Q55136811) (← links)
- Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins (Q73378147) (← links)
- Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR (Q77314879) (← links)